Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long term survival

Leukemia and Lymphoma

Volumn 42, Issue 1-2, 2001, Pages 67-73

  Giles, F J ^a   Shen, Y ^a   Kantarjian, H M ^a   Korbling, M J ^a   O'Brien, S ^a   Anderlini, P ^a   Donato, M ^a   Pierce, S ^a   Keating, M J ^a   Freireich, E J ^a   Estey, E ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Acute myeloid leukemia; Leukapheresis; Survival

Indexed keywords

ALBUMIN; ANTILEUKEMIC AGENT; BETA 2 MICROGLOBULIN; BILIRUBIN; CREATININE; CYCLOPHOSPHAMIDE; CYTARABINE; FIBRINOGEN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; LISOFYLLINE; RETINOIC ACID; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CLINICAL STUDY; CONTROLLED STUDY; CYTOGENETICS; DATA ANALYSIS; DRUG EFFICACY; HUMAN; LEUKAPHERESIS; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; PERFORMANCE; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PROGNOSIS; PUBLICATION; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0034928670     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190109097677     Document Type: Article

References (23)

1. Comparative prognosis of the acute leukemias
2. Causes of initial remission induction failure in acute myelogenous leukemia
3. Hyperleukocytic leukaemia: Rheological and clinical features and management
4. Acute myeloblastic leukemia with hyperleukocytosis: Risk factors for early mortality in induction
5. Management of hematological disorders and cancer
6. Therapeutic leukapheresis for hyperleukocytosis in acute myelocytic leukemia
7. Rapid cytoreduction in acute leukemia. Management of cerebral leukostasis by cell pheresis
8. Therapeutic leukopheresis of acute myelo-monocytic leukemia in pregnancy
9. Clinical course and response to treatment of patients with acute myelogenous leukemia presenting with a high leukocyte count
10. AML-associated cytogenetic abnormalities (inv (16), del (16)), t(8;21)) in patients with myelodysplastic syndromes
11. Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemia
12. Cytogenetic pattern in acute myelogenous leukemia: A major reproducible determinant of outcome
13. Long-term follow-up of patients with newly diagnosed acute myeloid leukemia treated at the University of Texas M.D. Anderson Cancer Center
14. Treatment of newly diagnosed AML, RAEB-t or RAEB with lisofylline or placebo in addition to chemotherapy
15. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony- stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
16. Effect of time to complete remission on subsequent survival and disease- free survival time in AML, RAEB-t, and RAEB
17. Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia
18. Pneumonia during remission induction chemotherapy in patients with AML or MDS
19. Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first
20. Goodness-of-fit and diagnostics for proportional hazards regression models
21. Therapeutic leukapheresis in the patient with leukemia
22. Complications of leukocytapheresis
23. Therapeutic leukapheresis in hyperleucocytic leukaemias: Lack of correlation between degree of cytoreduction and early mortality rate